



## DEPOSITARY RECEIPTS

### NEW DR ANNOUNCEMENT

January 23, 2015

### Symbio Pharmaceuticals Limited

Symbio Pharmaceuticals is a specialty biopharmaceutical company based in Japan. The Company specializes in the development and commercialization of drug candidates in oncology, hematology and autoimmunity areas. The Company has built pipelines (a group of newly developed drugs) with several pharmaceuticals, as well as, newly developed drugs in these disease areas. The Company's product pipeline includes SyB L-0501 (treatment of non-Hodgkin's lymphoma and mantle cell lymphoma); SyB L-1101/SyB C-1101, a multi-kinase inhibitor for the treatment of refractory/relapse myelodysplastic syndromes and solid tumor indications; and SyB D-0701, an antiemetic transdermal patch.

<b>Effective Date:</b>	January 23, 2015
<b>Country of Incorporation:</b>	Japan
<b>Exchange:</b>	OTC
<b>Type of ADR Program:</b>	Sponsored - Level I
<b>Ticker Symbol:</b>	SYMQY
<b>CUSIP Number:</b>	87150Y100
<b>Ratio (DR:ORD):</b>	1 : 1
<b>Underlying Share Description:</b>	Ordinary
<b>Industry Classification:</b>	Pharma. & Biotech.
<b>Custodian(s) :</b>	Mizuho Bank, Ltd.

To learn more about ADRs and issuer programs, please call our marketing desks:

#### New York

Ravi Davis  
Adrdesk@bnymellon.com  
Tel: 212 815 2267

#### Hong Kong

Herston Powers  
Vice President  
herston.powers@bnymellon.com  
Tel: 852 2840 9868

#### London

Damon Rowan  
Vice President  
damon.rowan@bnymellon.com  
Tel: 442071637511

Depository Receipts are not insured by the FDIC or any other government agency, are not deposits or other obligations of, and are not guaranteed by BNY Mellon and are subject to investment risks including possible loss of principal amount invested.

This announcement and the information contained herein is provided for general informational purposes only. BNY Mellon does not warrant or guarantee the accuracy, timeliness or completeness of this information. We provide no advice or recommendation or endorsement with respect to any company or securities. Nothing herein shall be deemed to constitute an offer to sell or a solicitation of an offer to buy securities. An offering is made by means of a prospectus only. BNY Mellon is regulated by the FSA.